Leukemia Clinical Trials in New York

Showing 621-640 of 850 trials

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931

The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.

LeukemiaLymphomaNeuroblastoma+2 more

Columbia University1 participantsStarted Sep 2007

New York, New York, United States

COMPLETEDPHASE1< 1 mile

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

NCT02492737

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation

Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies

Agios Pharmaceuticals, Inc.46 participantsStarted Aug 2015

Aurora, Colorado, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +3 more locations

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Leukemia Trials in Other Cities

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Early Diagnosis of Candidiasis in Premature Infants

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Other Conditions in New York